At the RAAD (Revolution Against Aging and Death) Festival in September 2025, Unlimited Bio Chief Technology Officer Anna Vakhrusheva unveiled why combination gene therapy may be humanity’s best chance to extend healthy lifespan well beyond 100 years.
Dr. Vakhrusheva highlighted that aging is a multifactorial process requiring multi-target interventions. She mentioned that Unlimited Bio has already developed four gene-therapy constructs – VEGF, Follistatin, Klotho, and BDNF – and is preparing to test them in unprecedented combination trials.
Key points from her speech:
Beyond Monotherapy. Tackling aging demands a systems approach, with therapies working synergistically.
Fast-Track Innovation. Unlimited Bio is leveraging Special Economic Zones like Próspera ZEDE (Roatán, Honduras) to cut regulatory delays and costs.
Bold Clinical Goals. The company aims to launch 100 clinical trials within 10 years, setting a new benchmark for longevity biotech.
“If we want a real chance at living past 100 in good health, we must move beyond incremental steps,” Vakhrusheva said. “Only bold, combinatorial approaches can reprogram aging biology at scale.”
Her presentation at RAAD reinforced Unlimited Bio’s position as one of the fastest-moving innovators in gene therapy for healthy longevity, signaling a new era of combinatorial biotech interventions.